Phase II trial of 3D-conformal accelerated partial breast irradiation: Lessons learned from patients and physicians鈥?evaluation

详细信息	查看全文 | 推荐本文 |

• 作者：Fares Azoury^a ; Steve Heymann^a ; Catalina Acevedo^a ; Marc Spielmann^b ; Philippe Vielh^c ; Jean-Ré ; mi Garbay^d ; Alphonse G. Taghian^e ; Hugo Marsiglia^a ; ^f ; Cé ; line Bourgier^a ; ^{bourgier@igr.fr}
• 关键词：3D-conformal APBI ; Cosmetic results ; Patients&rsquo ; satisfaction
• 刊名：Radiotherapy and Oncology
• 出版年：2012
• 期刊代码：231_01678140
• 类别：med
• 出版时间：May, 2012
• 卷：103
• 期：2
• 页码：193-198
• 文件大小：558 K

摘要

Introduction

The present study prospectively reported both physicians鈥?and patients鈥?assessment for toxicities, cosmetic assessment and patients鈥?satisfaction after 3D-conformal accelerated partial breast irradiation (APBI).

Materials and Methods

From October 2007 to September 2009, 30 early breast cancer patients were enrolled in a 3D-conformal APBI Phase II trial (40 Gy/10 fractions/5 days). Treatment related toxicities and cosmetic results were assessed by both patients and physicians at each visit (at 1, 2, 6 months, and then every 6 months). Patient satisfaction was also scored.

Results

After a median follow-up of 27.7 months, all patients were satisfied with APBI treatment, regardless of cosmetic results or late adverse events. Good/excellent cosmetic results were noticed by 80%of patients versus 92%of cases by radiation oncologists. Breast pain was systematically underestimated by physicians (8-20%vs. 16.6-26.2%; Kappa coefficient KC = 0.16-0.44). Grade 1 and 2 fibrosis and/or breast retraction occurred in 7-12%of patients and were overestimated by patients (KC = 0.14-0.27).

Conclusions

Present results have shown discrepancies between patient and physician assessments. In addition to the assessment of efficacy and toxicity after 3D-conformal APBI, patients鈥?cosmetic results consideration and satisfaction should be also evaluated.